Navigation Links
Ocular Therapeutix, Inc. Appoints Two New Board Members
Date:10/1/2009

WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey.

Mr. Myers is currently the President, CEO and co-founder of Alimera Sciences, Inc., a biopharmaceutical company that is developing and commercializing prescription ophthalmic pharmaceuticals. Under his leadership, Alimera has raised venture funding totaling approximately $90M. Myers has over 25 years of experience in the ophthalmic pharmaceutical industry in sales, marketing, and general management. "I am pleased to have the opportunity to contribute to the Ocular Therapeutix Board of Directors. The I-ZIP® Ocular Bandage has the potential to be of great benefit to patients in the future," said Myers.

Mr. Haffey was most recently President and CEO of NDO Surgical, a medical technology company dedicated to the development of innovative endoscopic technologies for gastrointestinal diseases. Prior to this position, he joined IntraLase Corp. as Vice President, Business Development. With over 10 years experience in medical technology, Haffey has a proven track record of successfully launching emerging medical technology and medical device companies. Additionally, he has successfully helped three of his former companies through acquisition including NDO Surgical and Intralase. "I am delighted to be joining the world-class team at Ocular Therapeutix and look forward to helping the company achieve world-class business results," said Haffey.

"We are extremely fortunate to add industry veterans such as Bernie and Dan to our board. While Bernie brings commercial leadership and expertise particularly in the refractive and corneal areas, Dan has deep expertise in ophthalmic pharmaceutical and drug delivery. Their addition to our team will be key as we move forward towards commercialization of the I-ZIP bandage in the US and as we build our drug delivery programs," said Amar Sawhney, President and CEO of Ocular Therapeutix. The appointment of Mr. Haffey and Mr. Myers increases the number of Ocular Therapeutix directors to seven. Board members also include Amar Sawhney, Fred Khosravi of Access Closure, Inc., Charles Warden of Versant Ventures, Sam Wu of SV Life Sciences, and Alan Crane of Polaris Ventures.

About Ocular Therapeutix, Inc:

Ocular Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. The company was founded in November 2006. The I-ZIP Adherent Ocular Bandage is CE Mark approved and the I-ZIP Ocular Bandage is under clinical investigation in the United States.

I-ZIP is a registered trademark of Ocular Therapeutix, Inc.

http://www.ocutx.com

SOURCE Ocular Therapeutix, Inc.


'/>"/>
SOURCE Ocular Therapeutix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
2. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
5. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
6. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
9. NovaRx Appoints Industry Veteran as President and COO
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):